Page 12 - MedTech 1920_29Oct
P. 12

One of the key strengths of Singapore’s R&D ecosystem lie in the strong partnerships between
our companies and the public sector. Global
and local start-ups, multinational corporations and local enterprises have been working closely with key public sector organisations, such as A*STAR, Institutes of Higher Learning (IHLs), Ministry
of Health (MoH), hospitals and the regulators to strengthen the growth and competitiveness of the MedTech industry.
Dickinson (BD) marked its 30th anniversary of manufacturing in Singapore with the opening of an advanced moulding centre, its  rst in Asia. Built within BD’s primary facility in Tuas, it is one of the largest and most sophisticated plastic moulding plants in the world with an annual production of 75 billion units of plastic components. Since its launch, BD has centralised and insourced most of its plastic moulding production in Asia.
In May, PerkinElmer opened its largest instrument manufacturing facility in Singapore. Housed at the JTC MedTech Hub, it has two demonstration laboratories where customers can have a hands-on experience with PerkinElmer’s technologies.
Singapore – hotbed for start-ups
Even as it rolls out the red carpet for multinationals, Singapore is also nurturing homegrown enterprises through key initiatives such as SEEDS Capital and Diagnostics Development (DxD) Hub.
Since 2014, SEEDS Capital, the investment arm of Enterprise Singapore which identi es and catalyses the growth of high-potential Singapore based start- ups, has co-invested over S$90 million in more than 20 MedTech start-ups.
The DxD Hub is a national initiative led by Agency for Science, Technology and
Research (A*STAR) which brings together clinicians, researchers, entrepreneurs and industry professionals onto a common platform to speed up the commercialisation of diagnostic technologies.
Today, Singapore is a veritable hotbed for MedTech as companies are leveraging arti cial intelligence (AI), information technology (IT), big data and precision engineering to develop better devices and diagnostics to improve the wellbeing of patients. Since the two initiatives were launched, the number of Singapore based MedTech companies has spiked, from about 100 in 2014 to more than 250 in 2018, with strong focus on in-vitro diagnostics, cardiology and ophthalmology. Start-ups account for over half the total.
Among the notable Singapore- based MedTech companies are Lucene Diagnostics, AWAK Technologies, Tricog and Ayzer Sense.
Lucence Diagnostics, a spin-off from A*STAR, is aiming to reduce avoidable cancer deaths through early detection using liquid biopsy. Unlike conventional tissue biopsy which requires tissue removal from the body, Lucence’s liquid biopsy tests are non-invasive, fast and affordable.
At the opening of its new 929-sq. metre laboratory in Singapore in January

   10   11   12   13   14